Abstract:Background: Malignant pleural mesothelioma (MPM) is characterized by therapeutically intractable loss-of-function mutations of tumor suppressor genes. Identification of actionable targets for the effective treatment of MPM remains an unmet clinical need. Methods: We integrated multi-omics data from patient samples of The Cancer Genome Atlas and Gene Expression Omnibus to identify cellular processes that exhibit oncogenic dependencies and particularly therapeutic vulnerabilities in MPM. Functional and mechanistic studies were pursued by genetic and pharmacological perturbations. The anti-MPM activity of combined therapy with MEK- and PARP-targeted drugs were assessed in vitro and in vivo in various mouse models. Findings: We discovered that mitogen-activated protein kinase kinase 1 (MEK1) functions as a previously unrecognized oncogenic driver in MPM, independent of tumor histological and genetic heterogeneity. Nevertheless, the efficacy of MEK-targeted therapies as single agents in MPM is compromised by a protective mechanism that involves PARP1. Mechanistically, MEK inhibition unmasks latent defects in genetic and metabolic homeostasis that manifest by impaired DNA homologous recombination repair and bioenergetic stress in mitochondria, which could be simultaneously restored by PARP1. Consequently, the combination of clinically approved MEK and PARP inhibitors exacerbates DNA damage and metabolic dysfunction, leading to synergistically enhanced MPM cell death and retarded tumor growth.Interpretation: Our study uncovers a previously unrecognized oncogenic driver and provides mechanistic insights for a readily translatable therapeutic strategy for the treatment of refractory MPM.Funding Information: This work was supported by grants from the Swiss Cancer League/Swiss Cancer Research Foundation (#KFS-4851-08-2019; to R-W. Peng), Swiss National Science Foundation (SNSF; #310030_192648; to R-W. Peng), and PhD fellowships from the China Scholarship Council (to H. Yang, Y. Gao and Z. Yang).Declaration of Interests: The authors declare that they have no conflict of interest.Ethics Approval Statement: All human studies were performed under the auspices of protocols approved by the institutional review board (KEK number: 042/15 and 200/2014), and informed consent was obtained from all patients as per protocol. Mouse studies were conducted in accordance with animal guidelines and protocols approved by the Institutional Animal Care and Ethical Committee.

MEK1 Drives Oncogenic Signaling and Interacts with PARP1 for Genomic and Metabolic Homeostasis in Malignant Pleural Mesothelioma.

Therapeutic Targeting of MEK1/2 Synergizes with PARP1 Inhibitors in the Treatment of Malignant Pleural Mesothelioma

Endoplasmic Reticulum Stress Signaling As A Therapeutic Target In Malignant Pleural Mesothelioma

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma

UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma

Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells

MA06.05 Targeting Anti-Apoptotic Mechanisms in Malignant Pleural Mesothelioma

A Subset of Metastatic Pancreatic Ductal Adenocarcinomas Depends Quantitatively on Oncogenic Kras/Mek/Erk-Induced Hyperactive Mtor Signalling

Malignant pleural mesothelioma co-opts BCL-X L and autophagy to escape apoptosis

APE-1/Ref-1 Inhibition Blocks Malignant Pleural Mesothelioma Cell Proliferation and Migration: Crosstalk between Oxidative Stress and Epithelial Mesenchymal Transition (EMT) in Driving Carcinogenesis and Metastasis

Biomarker-guided Targeted and Immunotherapies in Malignant Pleural Mesothelioma

PFKFB3 inhibition reprograms malignant pleural mesothelioma to nutrient stress-induced macropinocytosis and ER stress as independent binary adaptive responses

[Advances in Targeted Therapy for Malignant Pleural Mesothelioma]

2210P Reprogramming of Pyrimidine Metabolism Drives Tumorigenesis in NF2-deficient Malignant Pleural Mesothelioma

Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications

Interplay Of Mkp-1 And Nrf2 Drives Tumor Growth And Drug Resistance In Non-Small Cell Lung Cancer

Curcumin Induces Apoptosis and Inhibits Angiogenesis in Murine Malignant Mesothelioma

Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma

Nintedanib and Dasatinib Treatments Induce Protective Autophagy as a Potential Resistance Mechanism in MPM Cells

CRISPR screening identifies WEE1 as a combination target for standard chemotherapy in malignant pleural mesothelioma.